Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Latest News 2023-08-10-15-05
1-Feb-2023
Edison report: Reinvestment period with increased R&D focus
1-Nov-2022
Edison report: Q1 23 cash flows in line with our estimates
28-Oct-2022
New melanoma breakthrough by Kazia could potentially save thousands of lives
10-Oct-2022
Edison report: PNOC022 trial expanded
5-Sep-2022
Edison report: Doubling down on clinical development
8-Aug-2022
Interim data from MSKCC study
1-Aug-2022
GBM Agile Update
20-Jul-2022
Kazia recognises GBM Awareness Day 2022 as it expands clinical trial activity in Europe and US
12-Jul-2022
Kazia launches new SAB
17-Jun-2022
FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT
14-Jun-2022
Kazia paxalisib preclinical DIPG data released at IPSNO
8-Jun-2022
Kazia's Alliance study progresses to expansion phase
3-Jun-2022
Kazia presents final PII data at ASCO
31-May-2022
GBM Agile opens to paxalisib in Europe
24-May-2022
Edison Research: Deep Dive into Childhood Brain Cancer
23-May-2022
Kazia to present at investor conferences hosted by HC Wainwright and LD Micro
17-May-2022
Kazia marks DIPG Awareness Day
17-May-2022
Interview with Dr Matt Dun for World DIPG Awareness Day
29-Apr-2022
Kazia to present at ASCO
8-Apr-2022
Kazia presents preclinical data for paxalisib at AACR
8-Apr-2022
Kazia presents on EVT801 at AACR
21-Mar-2022
Kazia to present at two conferences
28-Feb-2022
First patient into Cornell keto study
31-Jan-2022
Quarterly Activities Report And Appendix 4c
19-Jan-2022
Kazia Corporate Presentation
7-Jan-2022
Kazia Therapeutics To Present At Hc Wainwright Bioconnect Conference
13-Dec-2021
Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer
3-Dec-2021
Kazia Announces Positive Final Data From Phase Ii Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
29-Nov-2021
Gbm Agile Opens To Paxalisib In Canada
15-Nov-2021
Kazia Therapeutics Appoints John Friend, Md, As Chief Medical Officer
11-Nov-2021
Pnoc Study In Childhood Brain Cancer Enrols First Patient
10-Nov-2021
Kazia Annual General Meeting Results
4-Nov-2021
Kazia Annual General Meeting Results
29-Oct-2021
Quarterly Activities Report And Appendix 4c
10-Sep-2021
Kazia Therapeutics To Present At Hc Wainwright 23rd Annual Global Investment Conference
2-Sep-2021
Evt801 Phase I Study Receives Full Regulatory Approval
30-Jul-2021
Quarterly Activities Report And Appendix 4c
21-Jul-2021
Kazia Calls For Increased Focus On Brain Cancer Research This Gbm Awareness Day
30-Jun-2021
Kazia Provides Progress Update On Paxalisib And Evt801 Clinical Programs
24-Jun-2021
Manufacturing Patents Granted For Paxalisib In Key Territories; Extend Effective Patent Protection To 2036
15-Jun-2021
Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma
7-Jun-2021
Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient
19-Apr-2021
Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se
29-Mar-2021
Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company
1-Mar-2021
Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab
7-Jan-2021
Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm
20-Dec-2020
Kazia Therapeutics Limited Appendix 4D Half-year report
